GNE-9815
CAS No. 2729996-45-4
GNE-9815( 3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide )
Catalog No. M28781 CAS No. 2729996-45-4
GNE-9815 is a high kinase-selective inhibitor of RAF and targets KRAS-mutant cancers through combination therapy.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 222 | Get Quote |
|
| 10MG | 357 | Get Quote |
|
| 25MG | 597 | Get Quote |
|
| 50MG | 851 | Get Quote |
|
| 100MG | 1152 | Get Quote |
|
| 500MG | 2313 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGNE-9815
-
NoteResearch use only, not for human use.
-
Brief DescriptionGNE-9815 is a high kinase-selective inhibitor of RAF and targets KRAS-mutant cancers through combination therapy.
-
DescriptionGNE-9815 is a high kinase-selective inhibitor of RAF and targets KRAS-mutant cancers through combination therapy.
-
In VitroGNE-9815 shows synergistic activity in KRAS mutant A549 and HCT116 cancer cells in combination with the MEK inhibitor Cobimetinib.
-
In VivoGNE-9815 (15 mg/kg; p.o.; single) demonstrates synergistic MAPK pathway modulation when combines with the MEK inhibitor Cobimetinib in an HCT116 xenograft mouse model.GNE-9815 (5 mg/kg; p.o.; single) shows good oral bioavailability and (1 mg/kg; i.v.; single) exhibits low blood clearance, moderate volume of distribution, and short half-life. Animal Model:Female NCR nude mice (6 to 8-week-old; 24-26 g; HCT116 xenograft mice model).Dosage:15 mg/kgAdministration:Intravenous injection or oral administration; single.Result:Resulted in pathway inhibition as demonstrated by partial inhibition of pRSK between 2 and 24 h, but more robust, albeit transient, inhibition of the downstream MAPK target genes, DUSP6 and SPRY4.Led to deeper inhibition of the downstream MAPK target genes DUSP6 and SPRY4, when combined with the MEK inhibitor Cobimetinib, with maximal inhibition at 8 h and with a more modest rebound in levels at 24 h, post final dose.Animal Model:Female NCR nude mice (6 to 8-week-old; 24-26 g).Dosage:1 mg/kg (for i.v.); 5 mg/kg (for p.o.).Administration:Intravenous injection or oral administration; single.Result:Exhibited CLb, Vdss and t1/2 values of 17 mL/min?kg, 1.7 L/kg and 1.9 h, respectively.Showed good oral bioavailability with F% of 37%. (methylcellulose/Tween formulation).
-
Synonyms3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2729996-45-4
-
Formula Weight455.48
-
Molecular FormulaC26H22FN5O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (109.77 mM)
-
SMILESN#CC(C=1C=CC=C(C1)C(=O)NC=2C=C(C3=CN=C4C(C=NN(C4=O)C)=C3)C(=CC2F)C)(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Gong J, et al. Salvianolic acid Y: a new protector of PC12 cells against hydrogen peroxide-induced injury from Salvia officinalis. Molecules. 2015 Jan 6;20(1):683-92.
molnova catalog
related products
-
Plx-4032
PLX-4032 is a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.PLX-4032 and its related analogs are highly potent inhibitors of B-Raf activity, with 3-fold selectivity for the V600E mutation over the wild-type kinase.
-
RAF-709
A novel potent, selective, and orally bioavailable RAF inhibitor with biochemical IC50 of 0.4 nM and 0.5 nM for BRAF and CRAF, respectively.
-
LY3009120
LY3009120 (DP-4978) is a potent pan-RAF and RAF dimer inhibitor with IC50 of 5.8, 9.1 and 15 nM for BRAF V600E, BRAF WT and CRAF WT, respectively.
Cart
sales@molnova.com